Steps taken after granting the Marketing Authorisation

For procedures finalised after 1 December 2002 please refer to module 8B.

- On 29 March 1999 the Marketing Authorisation Holder submitted an application for a Type II variation relating to the implementation of additional information in the relevant parts of the Summary of Product Characteristics and Package leaflet with respect to an interaction with ritonavir and saquinavir. The procedure started on 29 March 1999. The CPMP adopted a positive Opinion on 22 April 1999. The European Commission on 9 August 1999 issued a favourable Decision.
- On 5 August 1999 the Marketing Authorisation Holder submitted an application for two Type I variations relating to increase the batch size of the active substance of Viagra, sildenafil citrate and to extend the shelf-life of Viagra from 2 to 3 years. The procedure started on 11 August 1999. These variations were approved by the EMEA on 8 September 1999 and required amendments in the relevant sections of the Commission Decision. The European Commission amended the Decision on 14 December 1999.
- On 19 August 1999 the Marketing Authorisation Holder submitted an application for a Type II variation relating to the implementation of additional information in the relevant parts of the Summary of Product Characteristics and Package Leaflet with respect to hypersensitivity reactions, particular skin rashes and post-marketing experience with respect to cardiovascular and cerebrovascular events. The procedure started on 27 August 1999. The CPMP adopted a positive Opinion on 21 October 1999. The European Commission on 10 February 2000 issued a favourable Decision.
- On 25 January 2000 the Marketing Authorisation Holder submitted an application for a Type I variation to add an alternative site for assembly. The procedure started on 1 February 2000. The variation was approved by the EMEA on 23 February 2000. This variation was approved by the EMEA on 23 February 2000 and did not require any amendments to the Commission Decision. Changes were introduced in the summary of the dossier and in the manufacturing process documentation of the dossier.
- On 5 March 2000, the Marketing Authorisation Holder submitted an application for a Type II variation for the implementation of additional information in the relevant parts of the Summary of Product Characteristics, Labelling and Package Leaflet in response to a request from the CPMP following review of PSURs and monthly line listings, indicating the need to update the SPC and Package Leaflet. The variation concerned the use of sildenafil in combination with alphablockers and medicinal products with vasodilating properties, the use in patients with concomitant left ventricular outflow obstruction or multiple system atrophy (MSA), a potential interaction with azithromycin, and the occurrence of eye disorders. Some additional changes were made in order to comply with the EMEA templates. The procedure started on 17 March 2000. The CPMP adopted a positive Opinion on 25 May 2000. The European Commission issued a favourable Decision on 12 September 2000.
- On 21 August 2000, the Marketing Authorisation Holder applied for an alternative supplier for a starting material used in the synthesis of sildenafil. This variation falls within the scope of item No 11b of Annex I of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The procedure started on 29 August 2000. The EMEA considered this variation to be acceptable and issued on 28 September 2000 a positive Notification.
- On 21 August 2000, the Marketing Authorisation Holder applied to extend the shelf-life of Viagra from 3 to 4 years. This variation falls within the scope of item No 20 of Annex I of Commission Regulation (EC) No. 542/95 of 10 March 1995 as amended. The procedure started on 29 August 2000. The EMEA considered this variation to be acceptable and issued on 28 September 2000 a positive Notification.
- On 14 March 2001 the Marketing Authorisation Holder applied for the change of the name of a manufacturer of the active substance. This variation falls within the scope of item No. 11a of Annex I of Commission Regulation (EC) No. 542/95 of 10 March 1995 as amended.

The procedure started on 22 March 2001. The EMEA considered this variation to be acceptable and issued on 27 March 2001 a positive Notification.

- On 24 May 2001 the Marketing Authorisation Holder applied for changes to the SPC to include additional information available. The changes concern sections 4.8 (Undesirable effects), 5.1 (Pharmacodynamic properties) and 5.2 (Pharmacokinetic properties). The CPMP considered this Type II variation to be acceptable and adopted on 26 July 2001 an Opinion. The European Commission issued a favourable Decision on 27 November 2001.
- On 5th October 2001 the Marketing Authorisation Holder applied for an extension of shelf-life from 4 to 5 years. The procedure started on 12 October 2001. The EMEA considered this variation to be acceptable and issued on 9 November 2001 a positive Notification.
- On 14 November 2001 The Marketing Authorisation Holder applied for changes to the SPC and PL. This Type II variation relates to an update of section 5.1 of SPC to include additional information available on severe coronary artery disease and patients with erectile dysfunction and stable angina. The CPMP considered this Type II variation to be acceptable and adopted on 17 January 2002 an Opinion. The European Commission issued a favourable Decision on 18 April 2002.

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

Scope	Application number	Type of modification[1]	Notification/ Opinion issued on[2]	Commission Decision Issued/amended on
Change of Design of the Alum Foil	N/14	N	15 March 2002	-
Change following modification(s) to the manufacturing authorisation(s) – change in name of manufacturer.	I/15	I	8 October 2002	24 October 2002
Minor change in package leaflet not connected with the SPC (Art. 61.3 Notification)	N/16	N	15 November 2002	04 December 2002

[1] In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: **I** refers to a minor variation (Type I variation); **II** refers to a major variation (Type II variation); **I/II** refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; **X** refers to an Annex II application.
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

[2] For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.